Helicobacter pylori eradication with dual and low-dose triple therapy in patients with liver cirrhosis

Italian Journal of Gastroenterology and Hepatology

Volumn 31, Issue 9, 1999, Pages 831-835

  Zullo, A ^a   Rinaldi, V ^a   Meddi, P ^a   Winn, S ^a   Moscatelli, R ^a   Attili, A F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Dual therapy; Eradication; Helicobacter pylori; Liver cirrhosis; Triple therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE; TETRACYCLINE; UREASE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BURNING MOUTH SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EPIGASTRIC PAIN; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; STOMACH ANTRUM; STOMACH BIOPSY; TREATMENT FAILURE;

AMOXICILLIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES;

EID: 0033404029     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994;89(Suppl.8):Sl 16-28.
2. Graham DY, Lew GM, Klein PD, Evans DO, Evans DJ, Saeed ZA, et al. Effect of treatment of Helicobacter pylori infection on long-term recurrence of gastric or duodenal ulcer. Ann Int Med 1992;! 16:705-8.
3. Graham DV, Happs KS, Ramirez FC, Lew GM, Saeed ZA. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993;28:939-42.
4. Ricci C, Gatta L, Miglioli M, Vaira D. Therapeutic news on Helicobacter pylori from Budapest and Wien. Ital J Gastroenterol Hepatol 1998;30:648-62.
5. D'Amico G, Montalbano L, Traina M, Pisa R, Minozzi M, Spanò C, et al. Natural history of congestive gastropathy in cirrhosis. Gastroenterology 1990;99:155 8-64.
6. Kirchner GI, Wagner S, Schmidt H, Gevel M, Harms CP, Meier P, et al. Pathogenic role of Helicobacter pylori infection in chronic liver disease. Gastroenterology 1996;110:A157.
7. Zullo A, Rinaldi V, Meddi P, Folino S, Lauria V, Diana F, et al. Helicobacter pylori infection in dyspeptic cirrhotic patients. Hepato-Gastroenterol 1999;46:395-400.
8. Arns PA, Branch RA. Prescribing for patients with liver disease. Balliére's Clin Gastroenterol 1989;3:109-30.
9. Farrell G, Baird-Lambert J, Cvejic M, Buchanan N. Disposition and metabolism of metronidazole in patients with liver failure. Hepatology 1984;4:722-6.
10. Daneshmend TK, Homeida M, Kaye CM, Elamin AA, Roberts CJC. Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis. Gut 1982;23:807-13.
11. Farrell G, Baird-Lambert J, Cvejic M, Buchanan N. Impaired metronidazole elimination in decompensated chronic liver disease. BrMed J 1983;287:1845-9.
12. Chesta J, Defilippi C, Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology 1993;17:828-32.
13. Jaup BH, Norrby A. Comparison of two low dose one-week triple therapy regimens with and without metronidazole for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1996:10:275-7.
14. Bircher J, Sharifi S. Drug dosage in patients with liver disease. In: Mclntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, editors. Textbook of clinical hepatology. Oxford: Oxford Medical Publication; 1991. p. 1388-400.
15. Quero JC, Hartmann IJC, de Rooij F, Wilson JHP. Hyperammonaemia and Helicobacter pylori. Lancet 1995;346:713-4.
16. Dasani BM, Sigal SH, Lieber CS. Analysis of risk factor for chronic hepatic encephalopathy: the role of Helicobacter pylori infection. Am J Gastroenterol 1998:93:726-31.
17. Pugh RNH, Murray-Lyon IM, Dawson Jl, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973:60:646-9.
18. Japanese Research Society for Portal Hypertension. The general rules for recording endoscopie findings of esophageal varices. Jpn JSurg 1980:10:84-7.
19. Hashizume M, Kitano S, Yamaga H, Koyanagi N, Sugimachi K. Endoscopie classification of gastric varicies. Gastrointest Endosc 1990;36:276-80.
20. Me Cormick PA, Sankey EA, Cardin F, Dhillon AP, Mclntyre N, Burroughs AK. Congestive gastropathy and Helicobacter pylori: an endoscopie and morphometric study. Gut 1991;32:351-4.
21. Palmer ED. Portal cirrhosis: natural history of upper gastrointestinal bleeding. In Thomas J, editor. Upper gastrointestinal haemorrhage. Springfield, IL, USA; 1970. p. 176-89.
22. Dagradi AE, Meheler R, Ton DT. Source of upper gastrointestinal bleeding in patients with liver cirrhosis and large esophagogastric varices. Am J Gastroenterol 1970;54:458-63.
23. Graham DY, de Boer WA, Tytgat GNJ. Choosing the best antiHelicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 1996;91:1072-6.
24. Penston JG. Helicobacter pylori eradication: understandable caution but no excuse for exertion. Aliment Pharmacol Ther 1994:8:369-89.
25. Rinaldi V, Zullo A, Pugliano F, Valente C, Diana F, Attili AF. The management of failed dual or triple therapy for Helicobacter pylori eradication: a randomised, prospective study. Aliment Pharmacol Ther 1997;! 1:929-33.
26. Sung JJY, Chung S, Ling TKW, Suen R, Lueng VKS, Lau JYW, et al. Dual therapy versus triple therapy for Helicobacter pyloriassociated duodenal ulcers. Dig Dis Sci 1996;41:453-7.
27. Yang HB, Sheu BS, Su IJ, Chien CH, Lin XZ. Clinical application of gastric histology to monitor treatment of dual therapy in H. pylori eradication. Dig Dis Sci 1997;42:1835-40.
28. Tytgat GNJ. Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994;8:359-68.
29. McKee RF, MacGilchrist AJ, Garden OJ, Forrest JAH, Carter DC. The antisecretory effect and pharmacokinetics of omeprazole in chronic liver disease. Aliment Pharmacol Ther 1988;2:429-37.
30. Bayerdorffer E, Manness GA, Sommer A, Hochter W, Weingart J, Hatz R, et al. High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori. Eur J Gastroenterol Hepatol 1992;4:697-702.
31. Sarfeh IJ, Tamawsky A. Increased susceptibility of the portal hypertensive gastric rnucosa to damage. J Clin Gastroenterol 1991;13:S18-21.
32. Zullo A, Rinaldi V, Pugliano F, Diana F, Attili AF. Omeprazole plus clarithromycin and either tinidazole or tetracyclin for Helicobacter pylori infection: a randomized prospective study. Am J Gastroenterol 1997;92:2029-31.
33. Abbott Laboratories. Clarithromycin. Physicians Desk Reference, USA 49lh edition. 1995. p. 407-10.
34. Rinaldi V, Zullo A, De Francesco V, Hassan C, Winn S, Stoppino V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999;13:163-8.
35. Labenz J, Gyenes E, Ruhl GH, Borsh G. Amoxycillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized and controlled study. Gut 1993;34:1167-70.
36. Balzano A, Mosca S, Amitrano L, Di Blasi A, Piccirillo MM, Gigliotti T. Gastric antral erosions and Helicobacter pylori infection in cirrhotic patients: a pilot controlled study of oral bismuth vs ranitidine therapy. Ital J Gastroenterol 1991;23:132-5.
37. Nardone G, Coscione P, D'Armiento FP, Del Pezzo M, Pontillo M, Mossetti G, et al. Cirrhosis negatively affects the efficiency of sérologie diagnosis of Helicobacter pylori infection. Ital J Gastroenterol 1996;28:332-6.
38. Floreani A, Biagini MR, Zappalà F, Farinati F, Plebani M, Rugge M, et al. Chronic atrophie gastritis and Helicobacter pylori infection in primary biliary cirrhosis: a cross-sectional study with matching. Ital J Gastroenterol Hepatol 1997;29:13-7.
39. Fox JG, Wang TC. Helicobacter and liver disease. Ital J Gastroenterol Hepatol 1997;29:5-12.
40. Zullo A, Rinaldi V, Folino S, Hassan C, Pinto G, Attili AF. Helicobacter pylori and plasma ammonia levels in cirrhotics: role of urease inhibition by acetohydroxamic acid. Ital J Gastroenterol Hepatol 1998;30:405-8.